TrialsgrambetaRCTs are beautiful

PARTNER 3

2019

Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients

In 1,000 patients with severe AS at low surgical risk, TAVR with the SAPIEN 3 valve reduced death, stroke or rehospitalisation at one year versus surgical AVR.

Result

Efficacy: Death, stroke, rehospitalisationHR 0.54

Below 1 favours TAVR with the SAPIEN 3 valve, above 1 favours surgical AVR.

Event rates
Absolute difference
6.6 points

The absolute difference is derived from the event rates.

Original publication
Subtopic
TAVR
Design
RCT, 1 yr (non-inferiority + superiority)
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Mack MJ, et al. N Engl J Med. 2019;380(18):1695-1705.doi 10.1056/NEJMoa1814052

Discussion & critique

Driven largely by rehospitalisation. Longer-term durability data still maturing, relevant for younger, low-risk patients with decades of remaining life.

Discussed in podcasts